Magnetic material attracts attention for cancer therapy
Temperatures that can be tolerated by healthy body cells have long been known to destroy cancerous cells. …
Temperatures that can be tolerated by healthy body cells have long been known to destroy cancerous cells. …
Hansman’s research team recently discovered that a “nanobody” called Nano-85 was able to bind to intact norovirus-like particles (VLPs) in culture. …
HSCT (also known as blood and marrow transplant) is most often used to treat diseases of the blood and several types of cancer such as multiple myeloma or leukemia. For many people with these diseases the only possibility of a cure is to have a HSCT. The procedure provides healthy cells from either the patient (autologous transplantation) or from a healthy donor (allogeneic transplantation) to replace those lost to disease or chemotherapy…
Cancer data compiled by the World Health Organisation’s (WHO) GLOBOCAN project has huge global influence and is used by Governments and international NGOs to determine health and funding priorities in sub-Saharan Africa. However, no independent evaluation of the data has ever been undertaken. For the first time, experts from Queen Mary University of London have critically evaluated all publically available information on the quality of cancer registration systems in sub-Saharan Africa. …
Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes. The scientists believe that the validation of two urinary biomarkers could spell a new way of tailoring treatment…
Researchers used statistical software previously used in criminology studies of crime hotspots to track the extent to which the immune system was homing in and attacking breast cancer cells. The test, described in the journal Modern Pathology, could assess whether a woman’s immune system is holding a cancer at bay — and pick out those who will need intensive treatment to combat their more aggressive disease. Scientists at The Institute of Cancer Research, London, analysed tumour samples from 245 women with a type of breast cancer called oestrogen receptor negative (ER negative), which is particularly hard to treat. …
Scientists working in the Structural Bioinformatics and Network Biology Lab have included the more than 23,000 documented genetic mutations that affect the function of 2,000 proteins in an open-access web tool, and have positioned them on the map of known interactions between human proteins. dSysMap can be accessed free of charge at http://dsysmap.irbbarcelona.org, and scientists from around the world can add their data in an anonymous manner. Developed entirely at IRB Barcelona, dSysMap (“Disease-mutations Systemic Mapping”) provides molecular details about how mutations in certain proteins alter interactions with other proteins, thus affecting the correct funcion of cellular processes. The tool has explained, for example, why mutations in a single protein can cause two distinct diseases or why mutations in different proteins can trigger the same condition. …
“There are several reasons why some cancer stem cells, the cells at the root of tumors and metastases, can withstand therapy meant to eradicate them. Our results point to the importance of the environment immediately surrounding the skin cancer stem cells, specifically, their exposure to the signal TGF-β,” says senior researcher Elaine Fuchs. “Ultimately, we hope this new insight could lead to better means for preventing the recurrence of these life-threatening cancers, which can occur in the skin, head, neck, esophagus, and lung, and often evade treatment.” Her team, which included first author Naoki Oshimori, a postdoctoral research associate in the lab and lab technician Daniel Oristian, focused on squamous cell carcinomas in the skin of mice. Like many normal tissue stem cells, the stem cells that produce squamous cell tumors can be classified into two types: those that divide and proliferate rapidly, and those that do so more slowly. …
The researchers describe the Anderson Algorithm in a perspective piece outlining a personalized surgical approach to ovarian cancer published online at Nature Reviews Clinical Oncology. “Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that’s led to better results for our patients,” said Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine and senior author of the paper. The multi-step process was developed through MD Anderson’s Moon Shots Program, an ambitious effort launched in 2012 to dramatically reduce cancer deaths. Sood is co-leader of the Breast and Ovarian Cancer Moon Shot…
Clinical trials have established the benefit of giving chemotherapy prior to surgery (neoadjuvant chemotherapy) for patients with bladder cancer. However, clinical trials exploring giving chemotherapy after surgery (adjuvant chemotherapy) have been difficult to interpret and many of the trials closed early due to poor accrual without providing an answer. Lead researcher Matthew Galsky, MD and colleagues used a large database of patients diagnosed with cancer in the United States. Specifically, the study found that patients receiving adjuvant chemotherapy after surgical treatment had improved overall survival when compared to patients that received surgical treatment alone with only post-surgical observation. …